Back to Search Start Over

Decylglucoside-based microemulsions for cutaneous localization of lycopene and ascorbic acid

Authors :
Martha A. Hass
Emilee Bonnier
Tatjana Milic-Pasetto
Jessica Phelps
Jared DuJack
Kevin Lewis
Katrina Scarlett
Dominique Pepe
Luciana B. Lopes
Sumaya Jahan
Source :
International Journal of Pharmaceutics. 434:420-428
Publication Year :
2012
Publisher :
Elsevier BV, 2012.

Abstract

Cutaneous delivery of combinations of antioxidants offers the possibility of enhanced protection against UV-radiation. In this study, we investigated the potential of sugar-based microemulsions containing monoglycerides to promote simultaneous cutaneous delivery of lycopene and ascorbic acid, and increase tissue antioxidant activity. Lycopene and ascorbic acid were incorporated (0.04% and 0.2% (w/w), respectively) in decylglucoside-based microemulsions containing isopropyl myristate mixed with monocaprylin (ME-MC), monolaurin (ME-ML) or monoolein (ME-MO) as oil phase. The microemulsions increased lycopene delivery into porcine ear skin by 3.3- to 8-fold compared to a drug solution. The effect of microemulsions on ascorbic acid cutaneous delivery was more modest (1.5–3-fold), and associated with an approximately 2-fold increase in transdermal delivery. According to their penetration-enhancing ability, the microemulsions were ranked ME-MC > ME-MO > ME-ML. This superiority of ME-MC coincided with a stronger effect in decreasing skin electrical resistance. After 18 h of treatment, the viability of bioengineered skin treated with ME-MC was 2.2-times higher compared to Triton-X100 (moderate irritant), demonstrating that ME-MC is less cytotoxic. Skin treatment with ME-MC containing both antioxidants increased the tissue antioxidant activity by 10.2-fold, but no synergism between the antioxidants was observed.

Details

ISSN :
03785173
Volume :
434
Database :
OpenAIRE
Journal :
International Journal of Pharmaceutics
Accession number :
edsair.doi.dedup.....fa6dfdbc6e10b2430a28208d0fdfa209
Full Text :
https://doi.org/10.1016/j.ijpharm.2012.06.016